- Home
- CLLS vs LEO Comparison
CLLS vs LEO Comparison
Compare CLLS & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | LEO |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.2M | 388.1M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | LEO |
|---|---|---|
| Price | $3.69 | $6.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 44.3K | ★ 200.2K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | $152.00 |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $4.98 |
| 52 Week High | $5.48 | $6.50 |
Technical Indicators
Market Signals| Indicator | CLLS | LEO |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 65.44 |
| Support Level | $3.44 | $6.30 |
| Resistance Level | $3.98 | $6.54 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.28 | 89.58 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.